CalciMedica
CALC
0 hedge funds and large institutions have $0 invested in CalciMedica in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 26 closing their positions.
100% less funds holding
Funds holding: 26 → 0 (-26)
100% less capital invested
Capital invested by funds: $5.97M → $0 (-$5.97M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 26
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.64M |
| 2 |
O
OrbiMed
New York
|
-$2.08M |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$618K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$210K |
| 5 |
First Manhattan
New York
|
-$136K |
CALC Hedge Fund Activity: Q1 2023 in Review
0 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in CalciMedica (CALC) for Q1 2023, worth a combined $0 — down 100% from $5.97M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CALC and 0 opened new positions — a net loss of 26 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Deerfield Management, exiting entirely with an estimated $2.64M sold.
- 0 institutional investors held CalciMedica (CALC) as of Q1 2023, down from 26 in Q4 2022.
- Funds reported $0 of CalciMedica stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new CalciMedica positions in Q1 2023 and 26 closed out, a net change of -26 holders.
- The largest CalciMedica seller in Q1 2023 was Deerfield Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q1 2023.